Let's hear from the Board! I see this as a huge positive. Seems like SeD wants to grow their BioMedical arm and sees AMBS as a good way to get a foothold into U.S. market. In consideration for $500,000 convertible to shares at .025 cents (so 20,000,000 shares, nothing toxic it looks like), SeD is going to invest some of its own assets into AMBS and, most importantly, help AMBS pay off its debt and convertible preferred equity shares (MAGNA). Also, looks like we are going to get a whole new BoD, including a managing partner of Dominck & Dickerman. Seems like as excellent news, as now our BoD will have someone with experience managing money in biopharma (this was Gerald's biggest problem). And we have a new interim CFO, r. Ronald Wei, CPA, CFO at SeD Development Management, LLC.

Looks like great news to me.